title: Clinical evaluation of postoperative chemotherapy based on genetic testing in patients with stage IIIA non-small cell lung cancer.
abstract: BACKGROUND
  We performed a retrospective analysis to evaluate whether a postoperative chemotherapy selection method based on four tumoral gene expression tests would improve prognosis in patients with stage IIIA non-small cell lung cancer (NSCLC) after surgery.
  
  
  METHODS
  Between January 2007 and July 2011, 148 patients with stage IIIA NSCLC underwent radical lobectomy with four cycles of adjuvant postoperative chemotherapy. Forty-five patients had tailored treatment plans based on the results of tumoral gene expression tests. The tests consisted of quantitative real-time polymerase chain reaction analyses to measure the messenger ribonucleic acid levels of the excision repair cross-complementing gene 1, ribonucleotide reductase Ml, type III β-tubulin, and thymidylate synthase genes in tumor tissues. One hundred and three patients received conventional chemotherapy. Disease responses were assessed after two cycles and every three months after the first four cycles of chemotherapy. The one and two-year survival rates and diesease-free survival (DFS) rates were recorded, and the adverse effects documented.
  
  
  RESULTS
  The one and two-year DFS rates in the genetically tested group were better than those in the non-tested group, and the differences were statistically significant (P < 0.05). The two-year Kaplan-Meier DFS curve analysis results were significantly better in the genetically tested group (X(2) = 8.228, P = 0.004). The adverse effects during the treatments were not significantly different (P > 0.05) between the two groups.
  
  
  CONCLUSIONS
  The chemotherapy selection method based on four tumoral gene expression tests demonstrated its feasibility to improve the efficacy of adjuvant postoperative chemotherapy and benefit stage IIIA NSCLC patients by yielding better DFS without increasing the adverse effects of chemotherapy.
authors.affiliation: Department of Thoracic Surgery Beijing Chao-Yang Hospital Affiliated Capital Medical University Beijing China.
authors.forename: Jinbai
authors.initials: J
authors.lastname: Miao
authors.affiliation: Department of Thoracic Surgery Beijing Chao-Yang Hospital Affiliated Capital Medical University Beijing China.
authors.forename: Wenqian
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Thoracic Surgery Beijing Chao-Yang Hospital Affiliated Capital Medical University Beijing China.
authors.forename: Xiaoxing
authors.initials: X
authors.lastname: Hu
authors.affiliation: Department of Thoracic Surgery Beijing Chao-Yang Hospital Affiliated Capital Medical University Beijing China.
authors.forename: Shuo
authors.initials: S
authors.lastname: Chen
authors.affiliation: Department of Thoracic Surgery Beijing Chao-Yang Hospital Affiliated Capital Medical University Beijing China.
authors.forename: Bin
authors.initials: B
authors.lastname: Hu
authors.affiliation: Department of Thoracic Surgery Beijing Chao-Yang Hospital Affiliated Capital Medical University Beijing China.
authors.forename: Hui
authors.initials: H
authors.lastname: Li
keywords: Chemotherapy; non‐small‐cell lung cancer; postoperative; tumoral gene expression test
references.citation: Cancer Res. 1999 Aug 15;59(16):3968-71
references.pmid: 10463593
references.citation: Lancet Oncol. 2001 Sep;2(9):533-43
references.pmid: 11905707
references.citation: Lung Cancer. 2003 Aug;41 Suppl 1:S97-102
references.pmid: 12867068
references.citation: Clin Cancer Res. 2004 Feb 15;10(4):1318-25
references.pmid: 14977831
references.citation: Oncology. 2005;68(4-6):382-90
references.pmid: 16020967
references.citation: J Clin Oncol. 2007 Jul 1;25(19):2741-6
references.pmid: 17602079
references.citation: Lung Cancer. 2008 Mar;59(3):377-84
references.pmid: 17905465
references.citation: N Engl J Med. 2007 Oct 11;357(15):1559-61
references.pmid: 17928611
references.citation: Cancer Treat Rev. 2009 Feb;35(1):18-31
references.pmid: 18771857
references.citation: Cancer Sci. 2010 Jan;101(1):161-6
references.pmid: 19811498
references.citation: Lung Cancer. 2010 Jun;68(3):319-31
references.pmid: 20036027
references.citation: J Thorac Oncol. 2010 Mar;5(3):320-5
references.pmid: 20087230
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Clin Cancer Res. 2011 Aug 1;17(15):5205-14
references.pmid: 21690572
references.citation: Cancer. 2012 May 1;118(9):2525-31
references.pmid: 22028294
references.citation: PLoS One. 2013 May 13;8(5):e63338
references.pmid: 23675481
references.citation: J Clin Oncol. 2013 Jul 1;31(19):2404-12
references.pmid: 23690416
references.citation: Cancer Chemother Pharmacol. 2014 Oct;74(4):777-86
references.pmid: 25107571
references.citation: Cancer Chemother Pharmacol. 2014 Oct;74(4):839-46
references.pmid: 25119181
references.citation: Thorac Cancer. 2015 Jan;6(1):10-6
references.pmid: 26273329
references.citation: Thorac Cancer. 2012 Feb;3(1):19-26
references.pmid: 28920258